China vs Paraguay: Average cost of multi drug-resistant tuberculosis treatment
China
20,028 constant 2022 US$
in 2024
Paraguay
11,664 constant 2022 US$
in 2024
China rank
4th
Paraguay rank
5th
Average cost of multi drug-resistant tuberculosis treatment over time
- China
- Paraguay
How they compare
China currently reports 20,028 constant 2022 US$ against 11,664 constant 2022 US$ in Paraguay, a difference of 8,364 constant 2022 US$.
That makes China's figure about 1.7 times Paraguay's.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Paraguay ahead.
China ranks 4th and Paraguay ranks 5th of 92 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Paraguay | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,001 constant 2022 US$ | 2,559 constant 2022 US$ | 3,442 constant 2022 US$ | China |
| 2020s | 20,145 constant 2022 US$ | 4,347 constant 2022 US$ | 15,798 constant 2022 US$ | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, China or Paraguay?
- China, at 20,028 constant 2022 US$ against 11,664 constant 2022 US$ in Paraguay as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between China and Paraguay?
- 8,364 constant 2022 US$, with China ahead.
- How many years of comparable data are there for China and Paraguay?
- 7 years are reported by both, from 2017 to 2024.
- How do China and Paraguay rank globally for average cost of multi drug-resistant tuberculosis treatment?
- China ranks 4th and Paraguay ranks 5th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.